PharmaCyte Biotech Replaces CBIZ With Grassi as Auditor

• PharmaCyte Biotech replaced CBIZ CPAs with Grassi as its independent auditor, effective October 14, 2026.
• Grassi will audit the fiscal year ending April 30, 2027; interim reviews begin with the quarter ending October 31, 2026.
• CBIZ’s audit reports for fiscal years ended April 30, 2026 and 2025 contained no adverse opinions, disclaimers or qualifications.
• No accounting or auditing disagreements arose during those years or the interim period through October 14, 2026.
• Previously disclosed material weaknesses involved insufficient segregation of the chief financial officer’s duties and inadequate management review controls.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007934), on October 16, 2026, and is solely responsible for the information contained therein.